Regeneron Pharmaceuticals (NasdaqGS:REGN) recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...

Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

“People with bullous pemphigoid live with unrelenting itch, blisters and painful lesions that can be debilitating and make it difficult to function daily. Moreover, current treatment options can be ...

Usefulness of BP180 NC16a enzyme-linked immunosorbent assay in the serodiagnosis of pemphigoid gestationis and in differentiating between pemphigoid gestationis and pruritic urticarial papules and ...

HOUSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Itafos Inc. (TSX-V: IFOS) (the “Company”) is pleased to announce that, further to its announcement of August 5, 2024, it has completed ...